Publications, Pharmaceutical
Why it is Time to Think Differently about Nasal Delivery of Biologics
4 Apr 2022
COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.
By: Gemma Budd (General Manager, Operation Management, Nanopharm) Irene Rossi (Nanopharm Ltd, An Aptar Pharma Company)
This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.
